Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in Pediatric and Young Adult ALK+ Solid Tumors
NCT04260009Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of brigatinib in anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumor (IMT) and solid tumor (3 arms), sponsored by Takeda. Primary endpoints: Maximum Tolerated Dose up to 35 days, Recommended Phase 2 Dose up to 35 days and 4 more. Planned start Sep 2020; status: withdrawn.
02
Drugs
brigatinib
03
Conditions
anaplastic large cell lymphoma (ALCL)inflammatory myofibroblastic tumor (IMT)solid tumor
Beyond the preview
Go deeper on NCT04260009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260009.